The discovery stage molecule, from the same soil bacterium that produced oxytetracycline in the 1950s, blocks the ribosome's exit tunnel and shows an unusually low resistance rate in lab tests.
A soil-dwelling bacterium that gave medicine its first tetracycline antibiotic in the 1950s has produced another molecule that lands on a part of the bacterial ribosome no other known drug uses. In lab tests, fewer than one in a hundred million bacteria survived long enough to pass on genetic resistance to the new compound, called manikomycin.
The work, published this month in Nature, describes a cyclic depsipeptide made by Streptomyces rimosus, the same actinomycete behind oxytetracycline. Researchers at the University of Illinois Chicago, working with collaborators at McMaster University in Canada and the University of Hamburg in Germany, identified the compound by screening 255 strains from McMaster's Wright Actinomycetes Collection and refining how minor natural products are separated from more abundant ones. As the UIC release explains, the team was looking for overlooked molecules hidden in familiar soil bacteria.
What makes manikomycin unusual is not just that it is new, but where it binds. It attaches to the ribosome's E-site, the exit through which a finished protein leaves the machine. "It is a site that has never been targeted by any other molecule," first author Dmitrii Travin, a postdoctoral researcher at UIC's Retzky College of Pharmacy, said in the university release. By sitting on that exit, the drug blocks an essential step of protein synthesis.
That target matters because ribosomes are already the bullseye for roughly a third of the antibiotics doctors prescribe. Adding a previously untouched site to the map gives medicinal chemists a fresh handle, especially against pathogens that have learned to evade the older ones. In the new study, manikomycin worked against Escherichia coli and against antibiotic-resistant Klebsiella pneumoniae, a frequent cause of hard-to-treat pneumonia. It did not work well against most Gram-positive bacteria, including staph.
The resistance numbers are the most striking part of the dataset. The team measured resistance frequencies of about 3.7 in 10 billion for E. coli BW25113 and 1.1 in 100 million for K. pneumoniae C1559, according to the Nature paper. The authors attribute the rarity to the novel binding site and to manikomycin entering bacterial cells through several transport pathways, so a single mutation cannot easily disarm it. Even so, the strains tested were laboratory backgrounds, not clinical isolates, which is a meaningful gap between the bench and the clinic.
The compound is not a drug, and the authors are not claiming it is. The UIC team notes that the peptide breaks down quickly in the bloodstream, which means it cannot yet be given to patients. The real value of the paper is the solved structure of the drug-ribosome complex, captured at high resolution by the Hamburg group, which gives chemists a concrete starting point for follow-up molecules with better pharmacokinetics. As the Gizmodo explainer notes, this is the Waksman screening platform of the antibiotic era's first decades, refurbished with modern fractionation.
Independent commentary has been measured. Medicinal chemist Derek Lowe, writing on the Science magazine blog "In the Pipeline", called manikomycin "a really good example" of an overlooked compound surfacing from a revived natural-products program, but warned that "it is not going to be a wonder drug" because of its narrow spectrum and pharmacokinetic limits.
What to watch next is whether medicinal chemistry can keep the E-site binding intact while making the molecule last longer in the body and broadening its reach. The Nature paper, the UIC press release, and the Gizmodo explainer all point to the same starting line: a binding site no other antibiotic has used, now mapped well enough to be designed against.